Qsemble Capital Management LP Takes $234,000 Position in Repligen Co. (NASDAQ:RGEN)

Qsemble Capital Management LP bought a new position in shares of Repligen Co. (NASDAQ:RGEN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,853 shares of the biotechnology company’s stock, valued at approximately $234,000.

Several other large investors have also recently bought and sold shares of RGEN. Principal Securities Inc. purchased a new stake in shares of Repligen during the 4th quarter worth approximately $48,000. Dimensional Fund Advisors LP lifted its position in Repligen by 5.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 301,968 shares of the biotechnology company’s stock valued at $54,306,000 after acquiring an additional 16,430 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its stake in Repligen by 6.7% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 3,921 shares of the biotechnology company’s stock valued at $705,000 after acquiring an additional 245 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Repligen by 0.3% during the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 22,178 shares of the biotechnology company’s stock worth $3,805,000 after purchasing an additional 62 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Repligen by 93.9% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 6,502 shares of the biotechnology company’s stock worth $1,169,000 after purchasing an additional 3,149 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on RGEN shares. Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $190.00 price target on shares of Repligen in a research note on Wednesday, July 31st. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Repligen from a “hold” rating to a “buy” rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Wednesday, June 26th. Finally, Stephens reaffirmed an “overweight” rating and set a $170.00 price objective on shares of Repligen in a research note on Tuesday, July 30th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $188.38.

Insider Transactions at Repligen

In other news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares in the company, valued at approximately $3,190,969.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Repligen news, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the sale, the vice president now directly owns 19,261 shares of the company’s stock, valued at $3,190,969.87. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. The disclosure for this sale can be found here. Corporate insiders own 1.20% of the company’s stock.

Repligen Trading Down 1.4 %

NASDAQ RGEN opened at $139.99 on Friday. The company’s fifty day simple moving average is $145.43 and its 200-day simple moving average is $157.11. The stock has a market cap of $7.84 billion, a P/E ratio of 559.98, a PEG ratio of 4.24 and a beta of 0.94. Repligen Co. has a 52 week low of $110.45 and a 52 week high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million for the quarter, compared to analyst estimates of $154.11 million. During the same period in the previous year, the company earned $0.53 earnings per share. The company’s revenue for the quarter was down 3.2% compared to the same quarter last year. Equities research analysts predict that Repligen Co. will post 1.45 EPS for the current fiscal year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.